Marc is passionate about creating novel biomedical ventures. Today, he is focused to launch ventures in the fields of pediatric-first platform technologies, oncology and longevity. He is a co-founder at Rejuveron Senescence Therapeutics AG, Ninevah Therapeutics Ltd and Senolytic Therapeutics Inc. Marc is a Board member or strategic advisor at Aptadel Therapeutics, Retinset Therapeutics, Cyclomed, Gate2Brain, Cebiotex and GeneTether. He is a co-founder and Partner at Chasing Science, an early-stage biomedical venture builder.

Marc was also a founder and Advisor at Tech & Business Innovation (TBI), an academic firm focused on knowledge exchange and corporate-academic partnerships. He also supported investments and strategic partnerships at Life Biosciences Inc. in Europe. Marc brings experience as advisor and board member for multiple organizations and as co-founder of several companies. Marc has implemented Entrepreneurs-in-Residence programs at several academic institutions such as IRB Barcelona. From 2010 to 2012, Marc was working for Isis Innovations/University of Oxford as an associate consultant in Spain and LATAM. From 2007 to 2011, Marc was working at Endor, a nanomedicine company based in Spain. During this period, he was R&D director (drug-delivery nano-systems for cancer therapy) and Business Development Director (launched several nanotechnology products to the cosmetic and textile markets).

Previously, Marc also worked in the pharmaceutical environment in Novartis. He also collaborated with other research institutions such as Cancer Research UK and Boston College during his academic career. Marc gained a DPhil in Biochemistry from the University of Oxford in 2006, and a Harvard Business School PLD Program in 2011. Marc also gained a M.Sc. in Chemical Engineering in 2001 and a B.Sc. in Chemistry from IQS (Barcelona) in 2000.

Gonzalo is a partner at Chasing Science, where he supports the development and creation of new biomedical companies.

He is Head of Operations and Discovery of Ninevah Therapeutics, a portfolio company developing gene therapies for orphan kidney diseases; and interim Head of Operations of Aptadel Therapeutics, another portfolio company developing an RNA-based platform to treat Ewing’s sarcoma and other cancers.

Biochemist by training with a PhD in Molecular Biology, Gonzalo is specialized in RNA biology, gene therapy and molecular oncology. He is the author/co-author of 16 articles with over 800 citations. Gonzalo gained practical entrepreneurial experience thanks to the CaixaImpulse acceleration program (2017) and executive training at ESADE Business School.

I’m a doctor in molecular biology with a passion for building new projects and companies. I co-founded an NGO in 2012 (Mou) and a startup in 2014 (retail industry). Since then, I’ve been involved in the inception, acceleration and funding of startups in the health sector.
I’ve evaluated more than 150 investment opportunities and I’ve participated in the investment rounds of 16 startups that together raised more than €12M.